# Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study

> **NCT01632904** · PHASE3 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 110 (actual)

## Conditions studied

- Polycythemia Vera

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Hydroxyurea (HU)
- **DRUG:** HU-placebo
- **DRUG:** Ruxolitinib-placebo

## Key facts

- **NCT ID:** NCT01632904
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2014-03
- **Final completion:** 2016-05
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2017-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01632904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01632904, "Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01632904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*